Key points are not available for this paper at this time.
Abstract The blood–brain barrier (BBB) is a highly regulated and efficient barrier that controls the mass transfer between blood and brain, severely limits brain penetration of systemically administered therapeutics. During the onset and progression of brain tumors, BBB alters, and the blood–brain tumor barrier (BBTB) forms. Though BBTB differs from BBB in certain aspects, such as neuronal connections and aberrant pericyte distribution, it retains critical aspects of BBB. Hence, one major challenge in the development of therapeutics for brain tumor is to achieve sufficient BBTB penetration thus improving the efficiency of drug delivery to the tumor site. In this review, we summarize the strategies that can overcome BBTB and improve BBTB penetration efficiency from the perspectives of regulating BBTB structure and transport processes.
Song et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: